Novartis

Granite Bio is a biotechnology company focused on developing novel monoclonal antibody therapies targeting inflammatory, autoimmune, and fibrotic disorders.

Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on advancing therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in developing innovative treatments that target Factor XI and XIa, critical components of the intrinsic coagulation pathway. Its lead product, MAA868, is an anti-thrombotic investigational therapy designed to prevent thrombotic events while minimizing the risk of bleeding. By offering a long-acting treatment paradigm, Anthos Therapeutics aims to provide significant advantages over conventional standards of care, ultimately enhancing patient outcomes in cardiovascular health.

Alesta Therapeutics is a biotechnology company focused on developing cancer therapies by targeting stress response pathways and metabolic dependencies that sustain cancer cell survival. It develops small molecule programs to address novel targets within chronic stress responses and synthetic lethal metabolic dependencies in cancer, with the aim of shutting down survival pathways that cancer cells rely on for growth.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Borealis Biosciences is a biotechnology company focused on developing next-generation RNA-based therapies for kidney diseases. It specializes in molecular and cellular biology, vivarium space, chemistry, and analytical capabilities to enhance the delivery of RNA medicines to specific cell types.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

FundaMental Pharma is a neuroscience company developing novel drugs targeting neurodegeneration. Its portfolio focuses on preclinical stage therapies designed to uncouple the physiological function of glutamate-gated NMDA receptors from their toxic effects, aiming to stop neurodegeneration and improve brain health.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

Hyku is a biotechnology company specializing in the development of precise covalent targeting of disease-causing proteins. Its platform identifies molecules that covalently bind non-cysteine amino acids, enabling the creation of innovative medicines designed to address challenges such as selectivity, druggability, and resistance across various diseases.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

RxLightning is a digital platform that automates and streamlines the enrollment process for starting patients on specialty medications. The solution digitizes enrollment for various specialty therapies across fields such as addiction medicine, cardiology, endocrinology, and dermatology, helping healthcare providers reduce paperwork and speed up access to therapy.

Flare Therapeutics is a biotechnology company that develops small-molecule medicines by targeting transcription factors. It focuses on identifying switch sites—druggable regions that regulate transcription factor activity—to address disease-causing mutations. Leveraging insights into transcription factor biology, Flare aims to translate this understanding into precision medicines, building an early pipeline that is initially focused on precision oncology with potential expansions into neurology, rare genetic disorders, immunology, and inflammation. The company combines a drug-discovery platform with a biology-led approach to discover therapies that alter the trajectory of diseases driven by transcription factor dysregulation.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development. It specializes in innovative medicines for diseases with high unmet medical needs, initially concentrating on oncology and immunotherapies. The company operates research facilities in Waltham, MA, USA, and Ghent, Belgium, led by an experienced team of entrepreneurs and scientists.

Alladapt Immunotherapeutics is a privately held biopharmaceutical company focused on developing prescription therapeutics for food allergy. Based in Menlo Park, California, it was founded in 2018. The company’s lead program, ADP101, is a broad-spectrum oral immunotherapy designed to mitigate, treat, and prevent reactions to foods by targeting single or multiple allergen proteins across common allergens.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.

XOMA Corporation is a biotechnology company that operates as a royalty aggregator, discovering and developing antibody-based therapies and licensing future economics or rights to pre-commercial candidates to pharmaceutical and biotechnology partners. It maintains a pipeline of monoclonal antibody programs and provides antibody discovery, optimization, and development technologies under collaboration with partners. Notable candidate programs include X213, an allosteric prolactin inhibitor; XMetA, an insulin receptor–activating antibody for long-acting reduction of hyperglycemia in Type 2 diabetes; an IL-2–based therapy for metastatic melanoma and renal cell carcinoma; and a PTH1R program addressing primary hyperparathyroidism and related conditions. The company collaborates with large pharma entities such as Novartis, Rezolute, and Takeda to advance clinical development. Founded in 1981, XOMA is headquartered in Emeryville, California, and operates with regional reach across the United States, Europe, Asia Pacific, and other markets.

Dunad Therapeutics is a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies. It provides a proprietary, tunable covalent chemistry platform that enables discovery and development of medicines that selectively and durably target disease drivers. The platform integrates disease biology with advanced chemistry to modulate protein stability and conformation, allowing the targeting of often undruggable proteins and enabling high-precision, durable therapeutic effects.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Expansion Therapeutics is a drug discovery and development company focused on creating small molecule medicines for RNA-mediated diseases. The company specializes in developing novel RNA-targeted drug candidates that aim to address a wide range of severe medical conditions. By leveraging its innovative technology, Expansion Therapeutics seeks to provide transformative oral treatment options, enhancing the therapeutic landscape for patients suffering from these complex diseases.

Arctos Medical, spun off from the University of Bern, focuses on developing innovative optogenetic therapies for treating genetic eye diseases leading to blindness. Their primary aim is to create accessible treatments for inherited retinal dystrophies (IRDs), enabling patients to potentially regain vision and improve their overall visual experience.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Soteria Biotherapeutics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company focuses on developing innovative immunotherapies, specifically next-generation conditionally active bispecific T-cell engaging antibodies aimed at treating patients with solid tumors. Utilizing its proprietary T-LITE™ platform, Soteria creates bispecific antibody therapies that are activated by small molecules, allowing for safer and more effective treatments. This technology facilitates pulsatile activity, which reduces side effects and enables higher dosing, ultimately enhancing the therapeutic potential for cancer patients.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Founded in 2017, Amphista Therapeutics is a biopharmaceutical company based in Motherwell, UK. It specializes in developing first-in-class cancer therapeutics using targeted protein degradation technology to selectively remove disease-causing proteins.

Credence MedSystems is a medical technology company specializing in drug delivery systems. It develops and manufactures safety syringes designed to enhance patient and caregiver safety, simplify commercialization paths for pharmaceutical partners, and reduce risks in healthcare settings.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), an essential enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage, working to create a series of first-in-class molecules that aim to reactivate this vital tumor suppressor. With proprietary development tools, Rappta Therapeutics is enhancing its capacity for rational drug design, thus providing therapeutic options for a variety of cancer types and certain important non-oncology conditions.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

mPharma is a healthcare company focused on enhancing access to affordable medications in emerging markets. Founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, mPharma collaborates with drug manufacturers, insurance providers, financial institutions, and governments to streamline the delivery of prescription drugs to consumers. The company offers a pharmaceutical data analytics platform that assists pharmacies in managing their inventory, prescribing medications, and reporting adverse drug reactions. By ensuring that high-quality chronic disease medications are consistently available at sustainable prices, mPharma aims to improve health outcomes for patients, doctors, and pharmacists alike.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Arctos Medical, spun off from the University of Bern, focuses on developing innovative optogenetic therapies for treating genetic eye diseases leading to blindness. Their primary aim is to create accessible treatments for inherited retinal dystrophies (IRDs), enabling patients to potentially regain vision and improve their overall visual experience.

The Medicines Company is a pharmaceutical firm dedicated to improving the treatment of critical care patients by offering innovative and cost-effective medicines to hospitals worldwide. The company's primary product, Angiomax, is an anticoagulant used in conjunction with aspirin for patients undergoing coronary angioplasty. Additionally, The Medicines Company markets Cleviprex, an injectable emulsion for managing blood pressure when oral medications are not suitable. In its development pipeline, the company has two late-stage products: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Furthermore, The Medicines Company is exploring a serine protease inhibitor, CU2010, which is currently in early-stage development.

SiO2 Materials Science is a manufacturer specializing in the design and production of precision-molded plastic containers that offer advanced gas barrier properties comparable to glass and reduced protein binding surfaces. The company employs a proprietary plasma-enhanced chemical vapor deposition (PECVD) technology to create a range of products, including syringes, vials, and blood tubes, as well as other customized solutions. This innovative approach allows clients in the medical field to develop and commercialize products effectively by integrating thin, transparent coatings or treatments on surfaces that come into contact with drugs.

Adicet Bio is a biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer treatment. Its pipeline includes ADI-001, targeting CD20 for autoimmune diseases and B-cell lymphomas, and ADI-270, targeting renal cell carcinoma.

Renovacor, Inc., established in 2013 and headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing transformative gene therapies for cardiovascular diseases. Currently in the preclinical stage, Renovacor's primary focus is on creating a recombinant adeno-associated virus (AAV)-based gene therapy targeting patients with dilated cardiomyopathy (DCM) caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This condition affects approximately 35,000 individuals in the United States and Europe, qualifying it as an orphan disease. Renovacor aims to improve patient outcomes by potentially preventing disease progression through a BAG3 gene replacement therapy, given the current five-year survival rate of only 50% for DCM patients despite standard care.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing small-molecule therapeutics for patients with rare and aggressive cancers, using a bioinformatics platform and next-generation sequencing to identify tumorigenic drivers and guide targeted therapies. The company is developing AL101, an intravenous gamma secretase inhibitor for Notch-activating tumors such as adenoid cystic carcinoma, which is in Phase II, and AL102, an oral gamma secretase inhibitor for desmoid tumors, in Phase I. Ayala has a collaboration with Novartis to advance AL102 for multiple myeloma. Founded in 2017, the company is headquartered in Rehovot, Israel.

Xiidra is a pharmaceutical company that specializes in the development of a prescription eye drop solution aimed at treating the signs and symptoms of dry eye disease (DED). The company produces a non-steroid eye drop formulation that specifically addresses the inflammation commonly associated with DED. By offering an effective treatment option for individuals suffering from this condition, Xiidra plays a significant role in improving patients' ocular health and overall quality of life.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on advancing therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in developing innovative treatments that target Factor XI and XIa, critical components of the intrinsic coagulation pathway. Its lead product, MAA868, is an anti-thrombotic investigational therapy designed to prevent thrombotic events while minimizing the risk of bleeding. By offering a long-acting treatment paradigm, Anthos Therapeutics aims to provide significant advantages over conventional standards of care, ultimately enhancing patient outcomes in cardiovascular health.

Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

Zikani Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for patients with limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at treating a range of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Founded in 2014 and originally known as Macrolide Pharmaceuticals, Zikani is headquartered in Watertown, Massachusetts. The company's antibiotic compounds leverage advancements in synthetic chemistry and microbiology to address serious, multi-drug resistant gram-negative infections, which are a significant cause of severe health issues in the United States. Through its innovative approach, Zikani Therapeutics seeks to enhance patient outcomes and expand therapeutic options for challenging medical conditions.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Expansion Therapeutics is a drug discovery and development company focused on creating small molecule medicines for RNA-mediated diseases. The company specializes in developing novel RNA-targeted drug candidates that aim to address a wide range of severe medical conditions. By leveraging its innovative technology, Expansion Therapeutics seeks to provide transformative oral treatment options, enhancing the therapeutic landscape for patients suffering from these complex diseases.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Advanced Accelerator Applications develops and commercializes molecular nuclear medicine products for diagnosis and therapy. Its portfolio includes radiopharmaceuticals like oxodotreotides, dotatate injections, and edotreotide solutions, targeting oncology, cardiology, and neurology. The company also offers theragnostic platforms for precision imaging and targeted therapies.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs in conditions such as X-linked adrenoleukodystrophy (X-ALD). Neurovia has created a selective thyromimetic agent aimed at treating X-ALD, a rare genetic disease that can lead to severe neurological deficits. By addressing these critical health challenges, Neurovia aims to improve the quality of life for patients affected by this condition.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Anaeropharma Science, Inc. is a biopharmaceutical company based in Chiyoda, Japan, founded in 2004. The company focuses on developing innovative therapeutics aimed at treating solid cancers by targeting hypoxic environments, utilizing its proprietary platform technology based on recombinant Bifidobacterium. This technology allows for the in situ delivery and production of therapeutic agents. Anaeropharma Science's product offerings include APS001F, which is designed for solid cancer treatment, as well as therapies in immuno-oncology and anti-ischemic solutions. The company's approach involves genetically enhanced bacteria that can thrive in the hypoxic regions of tumors, converting systemically administered pro-drugs into cytotoxic agents, thereby enhancing the effectiveness and safety of cancer therapies and addressing other diseases associated with hypoxia.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies that restore the brain’s natural rhythms by modulating T-type calcium channels (Cav3), which are implicated in various neurological and rare genetic diseases. The company, founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, has developed CX-8998, a drug that targets these calcium channels in the nervous system. Cavion's innovative approach also extends to cancer treatment, as the company was the first to create therapies that engage Cav3 for solid tumors, with preclinical successes leading to Phase 1 clinical trials in brain cancer. The company's neurology program aims to deliver a novel class of non-addictive, non-opioid T-type calcium channel antagonists for conditions like neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Cavion operates as a subsidiary of Jazz Pharmaceuticals plc, reflecting its commitment to advancing treatments that address critical medical needs in both oncology and neurology.

Encore Vision is a company based in Fort Worth, Texas, focused on developing innovative treatments for presbyopia, a common age-related eye condition. Founded in 2000, Encore Vision has been working on a proprietary technology aimed at restoring the flexibility of the eye lens through an eye drop treatment. This treatment is designed to reduce lens stiffness and viscosity, enabling patients to regain the ability to focus on nearby objects. The company's development efforts are supported by a robust intellectual property portfolio, including issued patents and numerous pending applications. Encore Vision has also made significant progress in preclinical studies, having completed in-vivo proof of concept in animal models and is advancing towards clinical trials in humans.

Ziarco, Inc. is a biotechnology company founded in 2012 and headquartered in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and it has established a product pipeline that includes a histamine H4 receptor antagonist program. This program targets various therapeutic areas, such as asthma, allergic rhinitis, pruritus, and skin diseases, providing innovative treatment options for conditions like atopic dermatitis and psoriasis. Through its research and development efforts, Ziarco aims to offer effective solutions for patients suffering from these challenging health issues.

Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that is developing drugs to treat inflammatory and thrombotic diseases. They are targeting the underlying disease mechanism for these disorders. Their target is the adhesion of white blood cells to sites of inflammation mediated by the binding of two proteins, P-selectin and PSGL-1. The company is in preclinical development of humanized antibodies to P-selectin and PSGL-1 for the treatment of acute and chronic inflammatory and thrombotic disorders. Unregulated inflammatory processes play a major role in the harmful effects of multiple inflammatory disorders.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, established in 2016. The company specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting inflammasomes, which are critical in the inflammatory process. Inflazome's innovative therapies are designed to block inflammasome signals, thereby addressing the root causes of inflammation. The company's portfolio includes treatments for a range of conditions, such as neurological disorders like Alzheimer's and Parkinson's, systemic inflammatory diseases, and certain orphan diseases. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG, further enhancing its capacity to deliver targeted therapies in the field of inflammatory diseases.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

IFM Therapeutics is a biotechnology company focused on developing small-molecule medicines that modulate the innate immune system to treat inflammatory and autoimmune diseases and cancer. Its approach combines in-house discovery with collaborations to target novel components of innate immunity. The company operates through subsidiaries and affiliates, including IFM Due, which concentrates on antagonists of the cGAS/STING pathway for inflammation, neuroinflammation, autoimmunity, and cancer, and IFM Discovery, an incubator pursuing a portfolio of genetically validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity, and fibrosis. By designing small molecules that precisely engage innate immune targets, IFM Therapeutics aims to improve patient immune responses and address difficult therapeutic areas.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

Adicet Bio is a biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer treatment. Its pipeline includes ADI-001, targeting CD20 for autoimmune diseases and B-cell lymphomas, and ADI-270, targeting renal cell carcinoma.

C4 Therapeutics is a biopharmaceutical company developing targeted protein degradation therapies using its proprietary Degronimid platform. This platform enables the selective destruction of disease-causing proteins, expanding the scope of treatable conditions and potentially reducing drug resistance. The company focuses on oncology indications and has strategic collaborations with industry leaders.